BidaskClub Upgrades Theravance Biopharma (TBPH) to Buy
Theravance Biopharma (NASDAQ:TBPH) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Thursday.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating and set a $29.00 price objective for the company in a research report on Monday, February 11th. Cantor Fitzgerald initiated coverage on shares of Theravance Biopharma in a research report on Monday, January 28th. They set a “buy” rating and a $55.00 price objective for the company. ValuEngine cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 22nd. Leerink Swann set a $38.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, October 23rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Theravance Biopharma currently has an average rating of “Buy” and a consensus target price of $43.40.
NASDAQ:TBPH opened at $27.56 on Thursday. The company has a current ratio of 3.26, a quick ratio of 3.08 and a debt-to-equity ratio of 6.52. The stock has a market capitalization of $1.53 billion, a PE ratio of -5.06 and a beta of 1.74. Theravance Biopharma has a twelve month low of $21.27 and a twelve month high of $35.48.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.